LegoBody: facile generation of bispecific and multi-specific antibodies
Lang, S.; Su, Y.; Bidlingmaier, S.; Lee, N.-K.; Liu, B.
Show abstract
Bispecific and multi-specific antibodies are capable of recognizing multiple ligands simultaneously or synergistically, creating complex biological interactions not achievable by monoclonal antibodies, thus expanding opportunities for novel therapy development. With the large number of monoclonal antibodies either approved or under clinical development, there are numerous opportunities to combine their specificities to further improve therapeutic potential. Although simple in concept, clinical development of bi- and multi-specific antibodies face several challenges, chief of which is how to efficiently and reliably produce bispecific and multi-specific antibodies with expected specificity and desired biophysical properties. In this study, we developed a modular approach that uses temporary linkers to enforce proper chain pairing and proteases such as thrombin to remove those linkers from the final product. Combined with the knob-into-hole design, we can generate IgG-like, bi- or multi-specific antibodies from any pre-existing monoclonal antibodies. The approach is highly versatile and applicable to any monoclonal antibody pair or panel, expediting evaluation and therapeutic development of bi- and multi-specific antibodies.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering 94%
- Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies 94%
- High throughput functional screening for next generation cancer immunotherapy using droplet-based microfluidics 94%
Similar papers in this journal
Similar papers in this journal
- A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy 95%
- A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificity 94%
- Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies 94%
Similar papers in this journal
- TSHR-targeting nucleic acid aptamer treats Graves' ophthalmopathy via novel allosteric inhibition 93%
- Massively parallel screening of TIR-derived peptides reveals vast TLR-targeting immunomodulatory peptides 92%
- Multifaceted proteome analysis at solubility, redox, and expression dimensions for target identification 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.